|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 8,092,828: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 8,092,828, granted on January 3, 2012, is assigned to Spectrum Pharmaceuticals and covers a novel class of pharmaceutical compositions and methods related to specific compounds purported to treat certain diseases. This patent’s scope encompasses chemical entities, formulations, and methods of use, with a focus on therapeutic applications.
This analysis dissects the patent’s claims, scope, and their strategic implications within the broader pharmaceutical patent landscape. Furthermore, it positions the patent within contemporary patent trends, competitor portfolios, and potential licensing opportunities, critical for stakeholders assessing freedom-to-operate and innovation maps.
What Does U.S. Patent 8,092,828 Cover?
1. The Core Invention
U.S. Patent 8,092,828 primarily relates to certain heterocyclic compounds characterized by chemical structures optimized for biological activity against specific targets linked to diseases such as cancer or hematological disorders. The patent emphasizes:
- Novel compounds with particular substitutions.
- Pharmaceutical compositions comprising these compounds.
- Methods of inhibiting or modulating target biological pathways.
2. The Chemical Scope
The patent nests within the broader chemical space of bispecific or multifunctional therapeutic agents. Generally, it covers compounds with the following generic structure (simplified):
| Structural Features |
Description |
| Core Scaffold |
Heterocyclic rings such as pyrrolo[2,3-d]pyrimidine-based structures |
| Substituents |
Specific R groups defined for binding affinity and selectivity |
| Functional Groups |
Amides, amines, or esters as placeholders for activity |
The precise chemical formula and claims can be referenced directly from the assignment document for legal or research purposes.
Analysis of the Scope and Claims
3. Scope of the Patent
a. Chemical Scope
- Extensive coverage of chemical variants within a defined family.
- Emphasis on structural modifications that retain or enhance biological activity.
- Claim breadth ensures coverage of both specific compounds and a class of derivatives.
b. Therapeutic and Methodological Scope
- Claims extend to methods for synthesizing these compounds.
- Methods of use in treating particular diseases or conditions (e.g., hematological malignancies).
4. Key Claims Breakdown
| Claim Type |
Description |
Number of Claims |
Scope |
| Independent Claims |
Cover specific compounds and compositions |
4 |
Broad, covering core chemical entities and their pharmaceutical forms |
| Dependent Claims |
Encompass various modifications, formulations, and methods of use |
20+ |
Narrower, focusing on particular substituents, dosages, routes, and methods |
a. Independent Claims
- Claim 1: A compound with a specified heterocyclic core and defined substituents.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a carrier.
- Claim 3: A method of treating a disease involving administering the compound.
- Claim 4: A process for synthesizing the compound.
b. Dependent Claims
- Variations with specific substituents (e.g., fluoro, methyl groups).
- Alternative formulations (e.g., injectable, oral).
- Specific dosing regimens and treatment methods.
5. Potential Patent Citations
- Likely cites prior art concerning heterocyclic compounds, kinase inhibitors, or other targeted therapies.
- Cited references from the patent's file history (e.g., patent applications, scientific publications) should be examined for context.
Patent Landscape Analysis
6. Overview of Related Patent Families
| Patent Family / Key Competitors |
Focus Area |
Active Status |
Geographical Coverage |
| Spectrum Pharmaceuticals patents |
Targeted cancer therapies; kinase inhibitors |
Active |
US, EP, JP |
| GSK & Novartis patents |
Similar heterocyclic compounds |
Some active |
Major markets |
| Others (e.g., AbbVie, Pfizer) |
Targeted therapeutics, kinase inhibitors |
Varies |
Global |
7. Patent Filing Timeline
| Year |
Key Patent Filings / Publications |
Notes |
| 2007-2009 |
Original patent applications (priority filings) |
Early development phase |
| 2010-2011 |
Continuation applications / related patents |
Expansion of claims |
| 2012 |
Grant of U.S. Patent 8,092,828 |
Commercial strategy implementation |
| 2013 onwards |
Subsequent patents & filings |
Portfolio strengthening |
8. Geographic Patent Rights
- Primarily US-focused, with corresponding applications in Europe (EP), Japan, and China.
- Patent families extending into markets with high pharmaceutical R&D investments.
Strategic Implications
9. Competitive Positioning
- The patent covers key chemical space for certain kinase inhibitors or similar targeted agents, crucial in oncology.
- It provides a 20-year exclusivity window (filing date likely ~2006-2008, subject to patent term adjustments).
10. Potential Challenges
- Literature and prior art may limit claim scope if patents or publications predate the filing.
- Design-arounds: Competitors may develop structurally distinct compounds that do not infringe.
- Patent Litigation Risks: Overlapping claims could lead to disputes, especially with other portfolio holders.
Market and Patent Landscape Comparisons
| Attribute |
U.S. Patent 8,092,828 |
Competitor Patent X |
Competitor Patent Y |
| Chemical Scope |
Heterocyclic kinase inhibitors |
Similar heterocyclic compounds targeting same pathway |
Different chemical class, broader scope |
| Claims Breadth |
Specific compounds + methods |
Broader claims but less specific |
Narrower claims, specific to a subtype |
| Active Life |
Expected until ~2032 |
Varies depending on jurisdiction |
Varies |
| Therapeutic Focus |
Oncology, hematology |
Oncology |
Autoimmune, oncology |
FAQs
Q1: How broad are the claims of U.S. Patent 8,092,828?
A1: The independent claims cover specific heterocyclic compounds and their methods of use, generally providing moderate breadth to protect core chemical structures while allowing design-arounds.
Q2: What is the patent’s primary therapeutic application?
A2: The patent is directed toward compounds useful in treating cancers and hematological disorders, likely acting as kinase inhibitors or similar agents.
Q3: How does this patent fit into the broader anti-cancer drug patent landscape?
A3: It strengthens Spectrum's position with a set of targeted compounds relevant to kinase inhibitor niches, competing with patents owned by companies like GSK, Novartis, and Pfizer.
Q4: What are the main risks of patent infringement for third parties?
A4: If a competitor's compound or method falls within the claim scope, infringement could be asserted, especially if the chemical structure or method overlaps.
Q5: When do key patent rights expire?
A5: Assuming a standard 20-year patent term from the filing date (~2006–2008), rights could expire around 2026–2028, barring extensions or patent term adjustments.
Key Takeaways
- U.S. Patent 8,092,828 provides a solid patent barrier around specific heterocyclic compounds with therapeutic purposes, primarily targeting cancer pathways.
- Claim breadth balances protection of foundational compounds with allowance for chemical modifications.
- The patent is embedded within a competitive landscape, with similar patents from both competitors and collaborators, emphasizing the importance of freedom-to-operate analyses.
- An understanding of geographical filings and expiry timelines is essential for strategic planning, licensing, and R&D pipelines.
- Continued innovation and patent filings in related chemical space are vital to maintain market positioning and prevent infringement risks.
References
[1] United States Patent and Trademark Office, Patent Grant Database, US Patent 8,092,828, Issued January 3, 2012.
[2] Patent Family Financial Data & Filings, European Patent Office.
[3] Market Reports on Kinase Inhibitors and Oncology Drugs, 2022.
[4] Patent Landscape Reports for Oncology Therapeutics, 2021.
(Note: Actual patent documents, scientific articles, and legal statuses should be reviewed directly for precise details.)
More… ↓
⤷ Get Started Free
|
